Initial testing of Aplidin by the pediatric pre-clinical testing program

Christopher L. Morton, Peter J. Houghton, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Catherine Billups, Malcolm A. Smith

Research output: Contribution to journalArticle

9 Scopus citations


Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.

Original languageEnglish (US)
Pages (from-to)509-512
Number of pages4
JournalPediatric Blood and Cancer
Issue number3
StatePublished - Sep 1 2009
Externally publishedYes



  • Aplidin
  • Developmental therapeutics
  • Pre-clinical testing

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Morton, C. L., Houghton, P. J., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Keir, S. T., Reynolds, C. P., Kang, M. H., Maris, J. M., Billups, C., & Smith, M. A. (2009). Initial testing of Aplidin by the pediatric pre-clinical testing program. Pediatric Blood and Cancer, 53(3), 509-512.